Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lentiviral hCD68-mCherry engineered hematopoietic stem cells
- Development stage
- Preclinical
- Lead developer
- Northwestern University
- Modality
- Stem Cell Therapies → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
lentiviral hCD68-mCherry engineered hematopoietic stem cells is a preclinical cell and gene therapy platform developed by researchers at Northwestern University. It consists of autologous hematopoietic stem cells (HSCs) transduced with a lentiviral vector containing the human CD68 (hCD68) promoter, which drives the expression of a transgene—in this specific research construct, the fluorescent reporter mCherry. The platform is designed for glioma immunotherapy, leveraging the natural ability of HSC-derived myeloid cells to infiltrate the tumor microenvironment and differentiate into tumor-associated macrophages (TAMs). The hCD68 promoter ensures that transgene expression is restricted to the macrophage lineage and is significantly upregulated within the immunosuppressive tumor microenvironment, providing a modular system for targeted delivery of therapeutic agents to glioblastomas and other macrophage-rich malignancies.
- Other names
- hCD68-mCherry engineered HSCshCD-68-mCherry engineered HSCshCD 68-mCherry engineered HSCslentiviral-based hematopoietic stem cell platform for macrophage-specific expression
02
Targets
CD68p (CD68 promoter)DNA
Beyond the preview
Go deeper on lentiviral hCD68-mCherry engineered hematopoietic stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lentiviral hCD68-mCherry engineered hematopoietic stem cells.